Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647217 · ClinicalTrials.gov registry record · Phase 1
Demodex Blepharitis Treatment Study
A Phase 1 study, sponsored by BioTissue Holdings.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01647217 is a Phase 1 study that has completed, run by BioTissue Holdings. The registered enrollment target is 17 participants.
The verdict
NCT01647217, a Phase 1 study, has completed, sponsored by BioTissue Holdings.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis (reducing ocular demodex counts and achieving the clinical improvement with minimal or no irritation).
Interventions
- OTHER Placebo
- DRUG Terpinen-4-ol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647217
The ClinicalTrials.gov registry entry for NCT01647217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioTissue Holdings, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01647217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01647217 about?
NCT01647217 is a clinical study titled "Demodex Blepharitis Treatment Study". This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis (reducing ocular demodex counts and achieving the clinical improvement with minimal or no irritation).
What is the current status of trial NCT01647217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-02. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01647217?
The interventions under investigation include: Placebo (OTHER), Terpinen-4-ol (DRUG).
Who is sponsoring clinical trial NCT01647217?
This trial is sponsored by BioTissue Holdings, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.